Pages that link to "Q36399718"

The following pages link to Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug (Q36399718):

Displaying 35 items.

• Membrane transporters in drug development (Q29616802) (← links)
• HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites (Q35012924) (← links)
• Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients (Q35758975) (← links)
• Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks (Q35759067) (← links)
• Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results (Q36289127) (← links)
• Ribonucleoside 3'-phosphates as pro-moieties for an orally administered drug (Q36452385) (← links)
• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. (Q36628549) (← links)
• Fosamprenavir calcium plus ritonavir for HIV infection (Q36839698) (← links)
• Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. (Q36852528) (← links)
• Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy (Q36930395) (← links)
• Prodrugs: design and clinical applications. (Q37064858) (← links)
• FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo (Q37083640) (← links)
• Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization (Q37298637) (← links)
• Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects (Q37335653) (← links)
• Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance (Q37481442) (← links)
• HIV protease inhibitors: recent clinical trials and recommendations on use. (Q37519715) (← links)
• Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy. (Q37780687) (← links)
• Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics (Q37866298) (← links)
• Methadone: a review of drug-drug and pathophysiological interactions (Q37950478) (← links)
• Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study (Q39295251) (← links)
• Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir. (Q39542690) (← links)
• Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients (Q41720226) (← links)
• Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers (Q42953409) (← links)
• Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study (Q44564339) (← links)
• Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). (Q45919623) (← links)
• Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2. (Q46729445) (← links)
• Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients (Q46770803) (← links)
• Proteases and protease inhibitors in infectious diseases (Q47576680) (← links)
• Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. (Q51321228) (← links)
• Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. (Q51472972) (← links)
• The expanding role of prodrugs in contemporary drug design and development. (Q52560078) (← links)
• [Approach to evaluating the clinical relevance of drug interactions in HIV-infected patients] (Q80130962) (← links)
• Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy (Q89517208) (← links)
• Catalytic Chemoselective O-Phosphorylation of Alcohols (Q89985265) (← links)
• Prodrugs: My Initial Exploration and Where It Led (Q100407662) (← links)